<DOC>
	<DOCNO>NCT00002402</DOCNO>
	<brief_summary>The purpose study see safe effective give AIDSVAX B/B AIDSVAX B/E , two potential HIV vaccine , HIV-negative volunteer .</brief_summary>
	<brief_title>A Study AIDSVAX B/B AIDSVAX B/E , Two Possible Vaccines</brief_title>
	<detailed_description>Patients randomize 1 2 follow arm administer 1 2 injection deltoid muscle 0 , 1 , 6 , 12 month : Arm A : Patients receive 1 3 dos AIDSVAX B/B vaccine ( MN rgp120/HIV-1 plus GNE8 rgp120/HIV-1 ) alum adjuvant . Arm B : Patients receive AIDSVAX B/E ( MN rgp120/HIV-1 plus A244 rgp120/HIV-1 ) vaccine alum adjuvant . Patients evaluate 1 hr , 3 day , 14 day immunization 18 month first immunization . An interim analysis perform patient receive second dose ( 1 month ) .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Aluminum Hydroxide</mesh_term>
	<criteria>Patients must : Be HIVuninfected men woman low intermediate risk HIV1 infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 1998</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>Dose-Response Relationship , Drug</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS Vaccines</keyword>
	<keyword>HIV Seronegativity</keyword>
	<keyword>Antigens , Viral</keyword>
	<keyword>Alum Compounds</keyword>
</DOC>